CN104042604A - New application of isomangiferin - Google Patents
New application of isomangiferin Download PDFInfo
- Publication number
- CN104042604A CN104042604A CN201410276831.1A CN201410276831A CN104042604A CN 104042604 A CN104042604 A CN 104042604A CN 201410276831 A CN201410276831 A CN 201410276831A CN 104042604 A CN104042604 A CN 104042604A
- Authority
- CN
- China
- Prior art keywords
- isomangiferin
- blood pressure
- new application
- lowering blood
- hypertensive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CDYBOKJASDEORM-HBVDJMOISA-N isomangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC1=CC(O)=C(O)C=C1C2=O CDYBOKJASDEORM-HBVDJMOISA-N 0.000 title claims abstract description 16
- ALKWDTQJMCZSSY-UHFFFAOYSA-N isomangiferin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)c4cc(O)c(O)cc4Oc23)C(O)C(O)C1O ALKWDTQJMCZSSY-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 230000036772 blood pressure Effects 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 description 11
- 230000001631 hypertensive effect Effects 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000025505 Pyrrosia Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000009633 chimonin Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000009112 niuhuang Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to the field of biological medicines and relates to a new application of isomangiferin for lowering blood pressure. Experimental results show that isomangiferin has the activity of lowering blood pressure and is expected to be developed into new preparations for lowering blood pressure.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to the new purposes that Isomangiferin reduces blood pressure.
Background technology
Hypertensive sickness rate is approximately 20% adult.Hypertensive direct complication has cerebrovascular accident, renal failure, heart failure etc., and these complication mostly can disable or be lethal.Generally speaking, Hypertensive Population average life compared with normal crowd shortens 15～20 years.Malignant hypertension, as without treatment, can be dead in 1 year.
Treating hypertensive main purpose is to reduce to greatest extent cardiovascular and cerebrovascular vessel morbidity and dead total danger, therefore require doctor in the hypertensive while for the treatment of, intervene the clinical disease that all reversibility cardiovascular risk factors of patient, target organ damage and merging exist.For general hyperpietic's blood pressure lowering target, be below 140/90mmHg, for high risk patients such as complication with diabetes or nephropathy, blood pressure should be taken the circumstances into consideration to be down to more low-level in the tolerant situation of patient.
The line antihypertensive drug that World Health Organization (WHO) and China Treatment Guidelines for Hypertension are recommended is respectively: calcium antagonists, RAS depressant (comprising AT1 receptor antagonist and ACE inhibitor), receptor,β blocking agent, diuretic antihypertensive medicine, or the composite antihypertensive preparation of the fixed dosage being comprised of said medicine.Some Chinese medicine preparation, as Niuhuang Jiangya sheet etc., also have good curative effect to hypertension.
Summary of the invention
Folium Pyrrosiae is the dried leaves of Folium Pyrrosiae or pyrrosia petiolosaChing P.petio1osa (Christ) Ching, and all parts of the country are generally wild, main product in Zhejiang, the ground such as Hubei, Hebei.Remove rhizome and root, choose decontamination, wash away silt, dry or dry in the shade, cutting, raw using.Folium Pyrrosiae is containing cupreol, chimonin, Isomangiferin, Fumaric acid etc.
We find that Isomangiferin (Cas:24699-16-9) has the activity reducing blood pressure, therefore, and the new purposes that the object of the present invention is to provide Isomangiferin to reduce blood pressure.Further, for preventing and treating the hypertensive blood pressure reducing composition that contains Isomangiferin.
The specific embodiment
Embodiment 1. activity that reduces blood pressure
Spontaneous hypertensive rat is divided into 3 groups, and dosage regimen is in Table 1, and gastric infusion is arteria caudalis pressure measurement after 7 days.
Measurement data mean+SD
represent, between two groups, t check between relatively employing group, take P<0.05 as significance standard.
Result: Isomangiferin can effectively reduce spontaneous hypertensive rat blood pressure, relatively there were significant differences (seeing the following form) with model control group animal.
The impact of table 1. Isomangiferin on spontaneous hypertensive rat blood pressure
With model control group comparison
△p<0.05
Conclusion: show through experimental result, Isomangiferin has the activity of blood pressure lowering, is expected to be developed to new blood pressure lowering preparation.
Claims (2)
1. the new purposes that Isomangiferin reduces blood pressure.
2. the new purposes of Isomangiferin as claimed in claim 1, is characterized in that: the blood pressure reducing composition that contains Isomangiferin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410276831.1A CN104042604A (en) | 2014-06-19 | 2014-06-19 | New application of isomangiferin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410276831.1A CN104042604A (en) | 2014-06-19 | 2014-06-19 | New application of isomangiferin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104042604A true CN104042604A (en) | 2014-09-17 |
Family
ID=51496333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410276831.1A Pending CN104042604A (en) | 2014-06-19 | 2014-06-19 | New application of isomangiferin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042604A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873488A (en) * | 2015-05-29 | 2015-09-02 | 广西中医药大学 | Medicine with blood pressure reducing effect and production method of medicine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214254A (en) * | 2008-01-09 | 2008-07-09 | 昆明医学院 | New use of mangiferin compounds |
| WO2009125017A2 (en) * | 2008-04-11 | 2009-10-15 | Institut De Recherche Pour Le Développement (Ird) | Process for the extraction of mangiferin and isomangiferin |
-
2014
- 2014-06-19 CN CN201410276831.1A patent/CN104042604A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101214254A (en) * | 2008-01-09 | 2008-07-09 | 昆明医学院 | New use of mangiferin compounds |
| WO2009125017A2 (en) * | 2008-04-11 | 2009-10-15 | Institut De Recherche Pour Le Développement (Ird) | Process for the extraction of mangiferin and isomangiferin |
Non-Patent Citations (1)
| Title |
|---|
| 谭安雄: "芒果苷对易卒中型自发性高血压大鼠脑缺血再灌注后炎性因子的影响", 《中华高血压杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104873488A (en) * | 2015-05-29 | 2015-09-02 | 广西中医药大学 | Medicine with blood pressure reducing effect and production method of medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101411851B (en) | A traditional Chinese medicine composition for preventing and treating hyperlipidemia and atherosclerosis | |
| CN104042604A (en) | New application of isomangiferin | |
| CN104922611A (en) | Traditional Chinese medicine composition for treating arrhythmia and preparation method thereof | |
| CN101301357A (en) | Use of schisandra chinensis extract in anti-depression medicament | |
| CN104027331A (en) | New use of coixol in reduction of blood pressure | |
| CN103948744A (en) | Chinese medicinal composition for treating male infertility and preparation method thereof | |
| CN103417537A (en) | Purpose of dehydrogenation hirsutine | |
| CN103611095B (en) | A kind of Chinese medicinal ointment for the treatment of soft tissue injury | |
| CN101947263B (en) | Medicament for treating neurasthenia and insomnia | |
| CN105106317B (en) | The preparation and application of Southeast Asia herbal combination extract | |
| CN103989750A (en) | A pharmaceutical composition boosting animal immunity and a preparation method thereof | |
| CN102058668A (en) | Traditional Chinese medicinal preparation for treating primary thrombocytopenia | |
| CN104107242B (en) | A kind of Chinese medicine composition for the treatment of hyperthyroidism and its production and use | |
| CN102552481A (en) | Traditional Chinese medicinal composition with effects of smoothing collaterals and lowering blood pressure and preparation method thereof | |
| CN102008520A (en) | Drug for preventing and treating chronic mountain sickness and preparation method thereof | |
| CN102872051B (en) | Application of gypensapogenin A to antidepressant drugs | |
| CN103463115A (en) | Novel application of Salidroside | |
| CN103933034B (en) | A kind of pharmaceutical composition and application containing luteolin | |
| N’guessan-Irié et al. | Hyperglycaemia lowering activity and hypoglycaemic risk assessment of Sarenta, an Ivorian traditional herbal remedy | |
| Parikh et al. | Remodeling post Myocardial Infarction | |
| Blandizzi et al. | Gastrointestinal drugs | |
| CN107744577A (en) | A kind of Chinese medicine composition for treating mucosal lesion | |
| CN104013631A (en) | New use of cylindrin | |
| CN103432122A (en) | Application of isocorynoxeine in preparation of antihypertensive drugs | |
| CN104490982B (en) | A kind of eucommia bark depressor slow releasing preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140917 |